C

CSL

Develops and delivers biotherapies and vaccines

Senior Manager - Consolidation, Maternity Cover

Full-Time
No salary listed
Senior
Bachelor's
Liverpool, UK
HybridThree days on-site per week required.
AccountingFinancial Accounting

About the job

Requirements
  • A Bachelor's degree in Accounting, Finance or a related discipline is required.
  • An ACA, ACCA, CPA or equivalent professional accounting qualification is required.
  • At least 7 years of experience in financial accounting, consolidation, statutory reporting and audit is required.
  • At least 3 years of proven experience leading finance teams and managing complex stakeholder relationships is required.
  • Strong analytical, problem-solving and project management capabilities are required.
  • Demonstrated success in finance transformation, process improvement and implementation of financial controls is required.
Responsibilities
  • Lead the Account-to-Report team and co-lead the Vifor Consolidation function, ensuring accurate, timely and compliant financial reporting across a global portfolio of legal entities.
  • Lead global consolidation activities for Vifor entities under IFRS and Group reporting requirements across HFM/Hyperion and Finance Core.
  • Reconcile balance sheet and cash flow consolidation results between HFM and Finance Core, investigating and resolving variances.
  • Support the Financial Planning and Analytics team in reviewing financial results.
  • Own and oversee month-end, quarter-end, half-year and year-end close activities.
  • Ensure completeness and accuracy of financial information submitted to Group Reporting and other corporate stakeholders.
  • Co-lead consolidated balance sheet planning, ensuring data is consistent across relevant systems.
  • Support strategic finance transformation projects, including the migration of Vifor to Behring SAP through Project UNIFY, the transition from HFM/Hyperion to Finance Core, and adoption of the new planning system through Project Spark.
  • Lead the Account-to-Report team in preparing, reviewing and filing statutory financial statements.
  • Oversee and provide guidance on technical accounting assessments and key accounting judgements, including impairment reviews, provisions and complex accounting matters.
  • Ensure compliance with local regulatory requirements and evolving accounting standards, supported by external service providers where applicable.
  • Lead, coach and develop a team of accounting professionals, fostering a high-performance and continuous improvement culture.
  • Manage performance, objective setting, succession planning and development activities for direct reports, and provide guidance to indirect reports.
  • Support team capability building, including digital upskilling, automation and adoption of new technologies.
  • Allocate resources effectively to ensure delivery of key reporting, audit and project deadlines.
  • Act as a key finance partner to Tax, Treasury, Group Reporting, Shared Services and senior finance leadership.
  • Provide clear, practical insight on consolidation, statutory reporting and accounting matters to support effective decision-making.
  • Build strong relationships with internal and external stakeholders to support timely resolution of reporting, audit and compliance matters.
  • Maintain a strong internal control environment across the Vifor Account-to-Report and consolidation processes and support remediation of identified control weaknesses and process risks.
  • Drive compliance with CSL accounting policies, IFRS requirements and applicable control frameworks.
Desired Qualifications
  • Experience with consolidation systems is preferred, including experience working with SAP and HFM/Hyperion.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.